Future of Drug Development
Chris emphasizes the shift towards a classical education as essential for problem-solving in a world dominated by AI. The focus is on individuals who can synthesize diverse information rather than rote memorization. Recursion is committed to developing more drugs, despite industry hesitance towards new technologies, driven by regulatory challenges and high R&D costs.In this clip
From this podcast

The AI Podcast
Recursion CEO Chris Gibson on Accelerating the Biopharmaceutical Industry With AI - Ep. 230
Related Questions